Frequent KIT Mutations in Human Gastrointestinal Stromal Tumors.
Zhi Xu,Xinying Huo,Chuanning Tang,Hua Ye,Vijayalakshmi Nandakumar,Feng Lou,Dandan Zhang,Shouwen Jiang,Hong Sun,Haichao Dong,Guangchun Zhang,Zhiyuan Liu,Zhishou Dong,Baishuai Guo,He Yan,Chaowei Yan,Lu Wang,Ziyi Su,Yangyang Li,Dongying Gu,Xiaojing Zhang,Xiaomin Wu,Xiaowei Wei,Lingzhi Hong,Yangmei Zhang,Jinsong Yang,Yonglin Gong,Cuiju Tang,Lindsey Jones,Xue F. Huang,Si-Yi Chen,Jinfei Chen
DOI: https://doi.org/10.1038/srep05907
IF: 4.6
2014-01-01
Scientific Reports
Abstract:Identifying gene mutations in individual tumors is critical to improve the efficacy of cancer therapy by matching targeted drugs to specific mutations. Gastrointestinal stromal tumors (GIST) are stromal or mesenchymal subepithelial neoplasms affecting the gastrointestinal tract and frequently contain activating gene mutations in either KIT or platelet-derived growth factor A (PDGFRA). Although GIST is highly responsive to several selective tyrosine kinase inhibitors, combined use of inhibitors targeting other mutations is needed to further prolong survival in patients with GIST. In this study, we aim to screen and identify genetic mutations in GIST for targeted therapy using the new Ion Torrent next-generation sequencing platform. Utilizing the Ion Ampliseq Cancer Panel, we sequenced 737 loci from 45 cancer-related genes using DNA extracted from formalin-fixed and paraffin-embedded (FFPE) samples of 121 human gastrointestinal stromal tumors, set up stringent parameters for reliable variant calling by filtering out potential raw base calling errors, and identified frequent mutations in the KIT gene. This study demonstrates the utility of using Ion Torrent sequencing to efficiently identify human cancer mutations. This may provide a molecular basis for clinically developing new drugs targeting these gene mutations for GIST therapy.